[Herald Interview] After Sanofi deal, ABL Bio seeks to license out oncology treatment candidates
Jan 16, 2023
Korea Herald correspondent SAN FRANCISCO -- ABL Bio will release the results of early stage clinical trials regarding the company's oncology treatment candidates in this year, with hopes in license-out opportunities. “ABL Bio expects to introduce favorable clinical data regarding the company’s oncology treatment candidates,” ABL Bio CEO Lee Sang-hoon said on Thursday during an interview held on the sidelines of the 41th JPMorgan Healthcare Conference in San Francisco. ABL